SULFAMETHOXAZOLE AND TRIMETHOPRIM
LOE ApproachingNDAORALTABLET
Approved
May 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SULFAMETHOXAZOLE AND TRIMETHOPRIM by Fosun Pharma is clinical pharmacology sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. First approved in 1982.
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sulfamethoxazole and trimethoprim is a fixed-dose combination oral antibiotic that blocks two consecutive steps in bacterial nucleic acid and protein synthesis. It is indicated for prosthetic joint infections and other susceptible bacterial infections. The drug combines a sulfonamide (sulfamethoxazole) with a dihydrofolate reductase inhibitor (trimethoprim) for synergistic bactericidal activity.
LOE Approaching
As a mature generic approaching LOE, roles will focus on cost containment, supply chain optimization, and niche indication development rather than growth marketing.
Mechanism of Action
CLINICAL PHARMACOLOGY Sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. Both sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound and metabolized forms; sulfamethoxazole also exists as the conjugated form. Sulfamethoxazole is metabolized…
Worked on SULFAMETHOXAZOLE AND TRIMETHOPRIM at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.